Intracellular delivery of anti-BCR/ABL antibody by PLGA nanoparticles suppresses the oncogenesis of chronic myeloid leukemia cells. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.